



Original Article



Determination of Mean Blood Loss with Tranexamic Acid in Patients Undergoing Total Knee Arthroplasty

Muhammad Asjad Ali^{1*}, Shoaib Aslam², Syed Salman Saqlain³, Hafiz Salman Asif⁴, Muhammad Iqbal⁵, Hafiz Muhammad Asad Aslam⁶ and Sajid Hameed⁷

¹Sughra Shafi Medical Complex, Sahara Medical College, Narowal, Pakistan

²Department of Orthopedic Surgery, Sadiq Abbasi Hospital, Bahawalpur, Pakistan

³Department of Orthopedic, Sahiwal Teaching Hospital, Sahiwal, Pakistan

⁴Department of Trauma and Orthopedic, University Hospital Limerick, Limerick, Ireland

⁵Department of Orthopedic Surgery, Sharif Medical and Dental College, Lahore, Pakistan

⁶District Prison Hospital, Lodhran, Pakistan

⁷Department of Public Health, Green International University, Lahore, Pakistan

ARTICLE INFO

Keywords:

Tranexamic Acid, Knee Arthroplasty, Blood Loss, Orthopedic, Antifibrinolytic Therapy

How to Cite:

Ali, M. A., Aslam, S., Saqlain, S. S., Asif, H. S., Iqbal, M., Aslam, H. M. A., & Hameed, S. (2025). Determination of Mean Blood Loss with Tranexamic Acid in Patients Undergoing Total Knee Arthroplasty: Mean Blood Loss with Tranexamic Acid Total Knee Arthroplasty Patients. *Pakistan Journal of Health Sciences*, 6(5), 307-311. <https://doi.org/10.54393/pjhs.v6i5.2844>

*Corresponding Author:

Muhammad Asjad Ali
Sughra Shafi Medical Complex, Sahara Medical College, Narowal, Pakistan
drasjad13@gmail.com

Received Date: 6th February, 2025

Revised Date: 20th May, 2025

Acceptance Date: 27th May, 2025

Published Date: 31st May, 2025

ABSTRACT

Orthopedic surgeons routinely perform total knee arthroplasty (TKA). The use of antifibrinolytic therapy is one of the strategies to manage perioperative bleeding. TXA works by occupying the lysine-binding sites on plasminogen, thereby hindering its attachment to fibrin and ultimately halting the fibrinolysis process. Blood loss during gynaecological, cardiac, and orthopedic surgeries can be effectively managed with tranexamic acid. **Objectives:** To determine the average reduction in blood loss achieved with tranexamic acid in patients undergoing total knee arthroplasty. **Methods:** This interventional study was conducted over six months, from 25-08-2020 to 25-02-2021. A total of 60 patients from the OPD of the Orthopedic Department at Mayo Hospital, Lahore, were included in the study based on selected criteria. All participants signed informed consent forms. Demographic data were recorded, and TXA was administered after the surgery. All procedures were performed under general anesthesia. **Results:** The analysis showed that the average blood loss during surgery was 255.14 ml with the use of tranexamic acid. Excessive blood loss can have detrimental effects on a patient's health. **Conclusions:** It was concluded that tranexamic acid is effective in reducing bleeding during total knee replacement. Its use may also be more cost-effective compared to managing the consequences of significant blood loss.

INTRODUCTION

In joint reforming surgery, the damaged part of the joint is surgically removed or reshaped using osteotomy or the same process is done with various surgical techniques [1]. Usually, arthroplasty is carried out by choice to relieve pain and bring back movement in a joint that was damaged by arthritis or injury [2]. For most of the past 45 years, surgeons have most commonly and successfully repaired damaged joints by replacing the joint's surface with a prosthesis [3]. An illustration is when someone has

osteoarthritis of the hip, in which the surgeon may replace both the socket of the hip (acetabulum) and the upper part of the femur (the head and neck) with prosthetics [4]. During the operation, the objectives are to remove the pain, get the patient moving again, help walking and strengthen their muscles [5]. The loss of blood in this surgery is usually between 1,000 and 1,800 mL, so a transfusion is often necessary [6, 7]. Some studies have shown that after uncomplicated total knee arthroplasty, about 10% to 38%



of patients need allogeneic transfusions [8, 9]. Blood transfusion may cause problems with breathing and heart function, disease transmission, an immune reaction and postoperative infection [10]. Administration of tranexamic acid can be given locally or intravenously at the start of surgery, and it has been found to lower the amount of blood loss and the requirement for blood transfusion in this setting [11]. The total blood loss was reduced, and blood transfusion was not required. This painless and safe use of tranexamic acid means it controls the discharge of surplus blood efficiently after knee arthroplasty [12, 13]. Using tranexamic acid can help reduce bleeding after big surgical procedures. It is usually given to patients through a vein during total joint replacement. Even though there have been studies on how safe tranexamic acid is for its antifibrinolytic effect, it still should not be used systemically [14]. During a total knee arthroplasty, it is possible to inject tranexamic acid into the joint [15]. But, not many studies have been done on how much chemo to give, its effects, and what side effects it might cause [16]. Research by Bidolegui et al., 363.4 ± 141 milliliters of drain loss was found at 24 hours when using tranexamic acid [17]. Results found by Yen et al., suggested that the menstrual blood loss was 921 milliliters after tranexamic acid use, and this statistic was significant ($p < 0.05$) [18]. Literature reports that tranexamic acid may help lessen blood loss that results from a knee replacement. Sometimes, losing lots of blood can be harmful to both health and cost to the patient. Giving tranexamic acid is generally more economical than facing the expensive results of major blood loss. Furthermore, nothing local shows proof of this happening. That's why we needed to do this study, so in the future we can add tranexamic acid to the surgical procedure to help reduce blood loss. By doing this, our care will be better, and we will make sure to update local instructions for managing total knee replacement by including tranexamic acid.

Total knee arthroplasty (TKA) is frequently associated with substantial perioperative blood loss, which may increase the need for blood transfusion and lead to postoperative complications. Although tranexamic acid (TXA) has been reported to reduce blood loss in orthopedic procedures, evidence regarding its effectiveness in the local Pakistani population remains limited. Furthermore, variations in patient characteristics and healthcare settings may affect the generalizability of international findings. Therefore, this study aimed to determine the mean blood loss in patients receiving tranexamic acid during total knee arthroplasty and to provide local evidence regarding its effectiveness in reducing perioperative bleeding.

METHODS

From August 25, 2020, to February 25, 2021, which is six months, this interventional study took place in Unit I of the

Department of Orthopedic Surgery at Mayo Hospital in Lahore. The study focused on understanding the results of total knee replacement surgery for patients. A total of sixty cases were chosen to keep the error within 1%, achieve a 95% confidence level, and show that tranexamic acid reduced bleeding by an average of 921 ± 252 milliliters. The sampling method used was non-probability consecutive sampling. The inclusion criteria were patients who were 50 to 70 years old, of either gender, having a unilateral total knee replacement as outlined by the surgery description. Among the exclusion criteria were patients who had taken part in prior unsuccessful treatments or repeatedly fractured, patients with fractures that involved the entire bone (open fractures), those with severe double fractures of the knees (comminuted fractures), and those who required bilateral knee replacements. The ethical approval letter was taken from Green International University with registration No: IRC-GIU-155-04-2025. Informed consent was signed. Basic information about patients (name, age, gender, BMI, affected anatomical site, and duration of osteoarthritis) was collected before surgery, and 10 mg/kg of TXA was administered at the end of the procedure. All patients were placed under general anesthesia during surgery, which was carried out by a single surgical team with the researcher's assistance. An area of the wound was fitted with a suction drain to help remove excess blood. Post-surgery, patients remained in the post-surgical area to be carefully monitored for the next 24 hours. The suction drain was removed within a day, and the amount of blood drained was measured as defined by the operation. All the information about the study was recorded in a preform that had been prepared beforehand. The collected data were analyzed using SPSS version 23.0 to perform statistical analysis. The average values and standard deviation (SD) for age, BMI, and duration of osteoarthritis were reported as mean ± SD. The results for the qualitative variables (such as gender and the side of the body) were presented as frequencies and percentages. The groups were categorized based on age, gender, BMI, side of the affected joint, and the duration of osteoarthritis. The results from the post-stratification independent sample t-test were considered significant if the p-value was less than or equal to 0.050.

RESULTS

Studying the age of the patients, we found that 32 individuals (53.3% of the total sample), were 50-60 years old and 28 individuals (46.7%) were aged 61-70 years and had a calculated mean age of 60.18 ± 5.52 years. Also, examining the gender of the patients showed 38 (63.3%) were male and 22 (36.7%) were female (Table 1).

Table 1: Distribution of Age, Gender, and Anatomical Side (n=60)

Gender	Frequency (%)
Age	
50-60 Years	32 (53.3%)
61-70 Years	28 (46.7%)
Total	60 (100%)
Gender	
Male	38 (63.3%)
Female	22 (36.7%)
Total	60 (100.0%)
Anatomical Side	
Right	20 (33.3%)
Left	40 (66.7%)
Total	60 (100.0%)

During total knee arthroplasty, patients receiving tranexamic acid had a mean blood loss of 255.14 ± 81.68 ml (Table 2).

Table 2: Distribution of BMI, Duration of Osteoarthritis, and Blood Loss (n=60)

Variables	Mean \pm SD
BMI (kg/m ²)	25.66 \pm 2.16
Duration of Osteoarthritis (months)	9.00 \pm 4.23
Blood loss (ml)	255.14 \pm 81.68

The data were arranged by age, gender, body mass index, affected side and disease duration (Table 3).

Table 3: Stratification for Blood Loss Concerning Age, Gender, Anatomical Side, BMI and Duration of Osteoarthritis Using Independent Sample t-test (n=60)

Blood Loss	n	Mean \pm SD	SD Error Mean	p-Value
Age				
50-60 Years	32	243.22 \pm 74.286	13.132	0.230
61-70 Years	28	268.76 \pm 88.793	16.780	
Gender				
Male	38	254.01 \pm 87.722	14.230	0.336
Female	22	257.09 \pm 71.989	15.348	
Anatomical side				
Right	20	250.10 \pm 66.404	14.848	0.632
Left	40	257.66 \pm 89.032	14.077	
BMI				
17-25 kg/m ²	25	240.25 \pm 65.768	13.154	0.236
>25 kg/m ²	35	265.77 \pm 90.809	15.350	
Duration of Osteoarthritis				
≤ 12 Months	49	263.84 \pm 85.754	12.251	0.081
>12 Months	11	216.36 \pm 45.227	13.636	

DISCUSSION

Knee replacement surgery, which is also called knee arthroplasty or total knee replacement, replaces the surface of the damaged knee joint. While the procedure is being done, plastic and metal are positioned along the bone surfaces that make up the knee joint, such as the kneecap.

It's offered to someone who has serious arthritis or a major knee injury. Many forms of arthritis may cause problems in the knee. Usually, osteoarthritis occurs in adults over 40 due to losing the joint cushion, which worsens with time [19]. Synovial membrane inflammation caused by rheumatoid arthritis leads to excess fluid, pain and stiffness. A history of injury can lead to traumatic arthritis, which can damage the knee's cartilage. The objective of knee replacement surgery is to replace and cover up the parts of the knee that are damaged, and this helps relieve severe pain that other methods have not helped. Total knee replacement (TKR) is widely recognized as an effective and accepted way to treat knee osteoarthritis. It was found in the research that the age distribution of the patients put 53.3% of the patients (n=32) aged 50-60 years and 46.7% of them (n=28) aged 61-70 years. The average age was 60.18 ± 5.52 years. A greater number of males, 63.3%, were in the sample (38 participants), and fewer females, 36.7%, were in the sample (22 participants) [20]. Mean blood loss in those patients who received tranexamic acid was seen to be 255.14 ± 81.68 . Bidolegui et al., showed that the drain loss within 24 hours averaged 363.4 ± 141 ml in patients given tranexamic acid [17], while Yen et al., found it to be 921 ± 252 ml (p=0.014) [18]. In orthopedic surgeries, blood loss is commonly managed with TXA, because studies show it to help prevent and treat complications that occur while the patient is in the hospital. Numerous studies have been done to check if TXA is safe and effective for patients needing orthopedic surgery. When TXA was given peri-operatively to patients undergoing total hip arthroplasty (n=57), there was a 30% decrease in the need for transfusion when compared to a group receiving the placebo [21]. Many differences exist between developing countries and Western developed countries. In terms of age, physical appearance, how severe their condition is and their habits, patients in these two areas are different [22]. Also, when used in patients who do not do much physical activity, modern joint replacements with strong bearing surfaces may result in prolonged durability of the arthroplasty in developing countries [22]. Among a nationwide group of over 870,000 people who had elective total knee or hip arthroplasties in 510 U.S. hospitals, intravenous TXA used before or during surgery was not linked to a higher chance of any complication. Acute renal failure, dying in the hospital, heart attack, stroke and thromboembolic problems were the investigated issues. This is important because, besides demonstrating that TXA is safe in adults undergoing major orthopedic surgery, the authors also grouped patients by how much TXA was given (none, $\leq 1,000$ mg, 2,000 mg and $\geq 3,000$ mg). Studies found that TXA administration was closely linked to a significant decrease in blood transfusions, and odds ratios for this effect ranged from 0.31 to 0.38. The overall risk of

transfusion-related reactions (OR) for allogeneic transfusions was 0.29 to 0.37. Important to note, these patients had no important rise in the risk of different complications like combined complications, renal failure, admission to intensive care or the risk of thromboembolic events [23]. In the research, giving people a 2,000 mg dose of TXA was found to offer the best combination of results and safety. Nevertheless, some experts worry about the constant use of TXA in elderly patients who have surgery [24].

This study has several limitations, including a relatively small sample size, single-center setting, and the absence of a comparison or control group not receiving tranexamic acid. In addition, only short-term perioperative outcomes were assessed, limiting evaluation of long-term safety and effectiveness. Future studies should employ larger multicenter randomized controlled designs with appropriate control groups and longer follow-up periods to comprehensively assess the efficacy, safety, and cost-effectiveness of tranexamic acid in total knee arthroplasty patients.

CONCLUSIONS

It was concluded that for this study, researchers looked at how much blood the patients lost when tranexamic acid was used during total knee arthroplasty. Mean blood loss among the group using tranexamic was 255.14 ± 81.68 ml. Suffering from excessive bleeding can be very harmful to your health. Thus, we understood that tranexamic acid lessens bleeding after total knee replacement and may be more cost-effective than the problems of excessive bleeding.

Authors' Contribution

Conceptualization: MAA, SA

Methodology: MAA, HAS, SH

Formal analysis: MAA, SSS, SH

Writing and Drafting: MAA, SA, SSS, MI, HMAA

Review and Editing: MAA, SA, SSS, MI, HMAA

All authors approved the final manuscript and take responsibility for the integrity of the work

Conflicts of Interest

All the authors declare no conflict of interest.

Source of Funding

The author received no financial support for the research, authorship and/or publication of this article.

REFERENCES

- [1] Peng H, Ou A, Huang X, Wang C, Wang L, Yu T *et al.* Osteotomy around the knee: the surgical treatment of osteoarthritis. *Orthopedic Surgery*. 2021 Jul; 13(5): 1465-73. doi: 10.1111/os.13021.
- [2] Grayson CW and Decker RC. Total joint arthroplasty for persons with osteoarthritis. *Physical Medicine and Rehabilitation*. 2012 May; 4(5): S97-103. doi: 10.1016/j.pmrj.2012.02.018.
- [3] Klein J. Repair or replacement—a joint perspective. *Science*. 2009 Jan; 323(5910): 47-8. doi: 10.1126/science.1166753.
- [4] de l'Escalopier N, Anract P, Biau D. Surgical treatments for osteoarthritis. *Annals of Physical and Rehabilitation Medicine*. 2016 Jun; 59(3): 227-33. doi: 10.1016/j.rehab.2016.04.003.
- [5] Joelsson M, Olsson LE, Jakobsson E. Patients' experience of pain and pain relief following hip replacement surgery. *Journal of Clinical Nursing*. 2010 Oct; 19(19-20): 2832-8. doi: 10.1111/j.1365-2702.2010.03215.x.
- [6] Banasiewicz T, Machała W, Wysocki MB, Lesiak M, Krych S, Lange M *et al.* Principles of minimize bleeding and the transfusion of blood and its components in operated patients-surgical aspects. *Polski Przegląd Chirurgiczny*. 2023; 95(5). doi: 10.5604/01.3001.0053.8966.
- [7] Frank SM, Chaturvedi S, Goel R, Resar LM. Approaches to bloodless surgery for oncology patients. *Hematology/Oncology Clinics*. 2019 Oct; 33(5): 857-71. doi: 10.1016/j.hoc.2019.05.009.
- [8] Klika AK, Small TJ, Saleh A, Szubski CR, Pillai AL, Barsoum WK. Primary total knee arthroplasty allogeneic transfusion trends, length of stay, and complications: nationwide inpatient sample 2000-2009. *The Journal of Arthroplasty*. 2014 Nov; 29(11): 2070-7. doi: 10.1016/j.arth.2014.06.018.
- [9] Noticewala MS, Nyce JD, Wang W, Geller JA, Macaulay W. Predicting need for allogeneic transfusion after total knee arthroplasty. *The Journal of Arthroplasty*. 2012 Jun; 27(6): 961-7. doi: 10.1016/j.arth.2011.10.008.
- [10] Saleh A, Small T, Pillai AL, Schiltz NK, Klika AK, Barsoum WK. Allogeneic blood transfusion following total hip arthroplasty: results from the nationwide inpatient sample, 2000 to 2009. *The Journal of Bone and Joint Surgery*. 2014 Sep; 96(18): e155. doi: 10.2106/JBJS.M.00825.
- [11] Kim C, Park SS, Davey JR. Tranexamic acid for the prevention and management of orthopedic surgical hemorrhage: current evidence. *Journal of Blood Medicine*. 2015 Aug; 239-44. doi: 10.2147/JBM.S61915.
- [12] Hunt BJ. The current place of tranexamic acid in the management of bleeding. *Anesthesia*. 2015 Jan; 70: 50-e18. doi: 10.1111/anae.12910.
- [13] Charoencholvanich K, Siriattanasakul P. Tranexamic acid reduces blood loss and blood

- transfusion after TKA: a prospective randomized controlled trial. *Clinical Orthopedics and Related Research*. 2011 Oct; 469: 2874-80. doi: 10.1007/s11999-011-1874-2.
- [14] Roy SP, Tanki UF, Dutta A, Jain SK, Nagi ON. Efficacy of intra-articular tranexamic acid in blood loss reduction following primary unilateral total knee arthroplasty. *Knee Surgery, Sports Traumatology, Arthroscopy*. 2012 Dec; 20: 2494-501. doi: 10.1007/s00167-012-1942-5.
- [15] Zhang Y, Fu X, Liu WX, Li YM, Ma XL, Li ZJ. Safety and efficacy of intra-articular injection of tranexamic acid in total knee arthroplasty. *Orthopedics*. 2014 Sep; 37(9): e775-82. doi: 10.3928/01477447-20140825-53.
- [16] van den Boogaard WM, Komninou DS, Vermeij WP. Chemotherapy side-effects: not all DNA damage is equal. *Cancers*. 2022 Jan; 14(3): 627. doi: 10.3390/cancers14030627.
- [17] Bidolegui F, Arce G, Lugones A, Pereira S, Vindver G. Tranexamic acid reduces blood loss and transfusion in patients undergoing total knee arthroplasty without tourniquet: a prospective randomized controlled trial. *The Open Orthopedics Journal*. 2014 Jul; 8:250. doi: 10.2174/1874325001408010250.
- [18] Yen SH, Lin PC, Chen B, Huang CC, Wang JW. Topical tranexamic acid reduces blood loss in minimally invasive total knee arthroplasty receiving rivaroxaban. *BioMed Research International*. 2017; 2017(1): 9105645. doi: 10.1155/2017/9105645.
- [19] Lane NE and Wallace DJ. All about Osteoarthritis: The definitive resource for arthritis patients and their families. Oxford University Press. 2002 Mar. doi: 10.1093/oso/9780195138733.001.0001.
- [20] Surannavar J. The Effect of Tranexamic Acid on Haemoglobin Level During Surgeries Around Hip (Master's thesis, Rajiv Gandhi University of Health Sciences(India)). 2014.
- [21] Khan N, Troelsen A, Husted H. Prevention of post-operative anemia in hip and knee arthroplasty—a systematic review. *Danish Medical Journal*. 2015 Dec; 62(12): A5170.
- [23] Pedneault C, St George S, Masri BA. Challenges to implementing total joint replacement programs in developing countries. *Orthopedic Clinics*. 2020 Apr; 51(2): 131-9. doi: 10.1016/j.jocl.2019.11.001.
- [24] Poeran J, Rasul R, Suzuki S, Danninger T, Mazumdar M, Opperer M *et al*. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. *British Medical Journal*. 2014 Aug; 349. doi: 10.1136/bmj.g4829.
- [25] Fillingham YA, Ramkumar DB, Jevsevar DS, Yates AJ, Shores P, Mullen K *et al*. The safety of tranexamic acid in total joint arthroplasty: a direct meta-analysis. *The Journal of Arthroplasty*. 2018 Oct; 33(10): 3070-82. doi: 10.1016/j.arth.2018.03.031.